Publications by authors named "Sandy Liaw"
Article Synopsis
- The study investigates ABI-H0731, a new drug aimed at treating hepatitis B virus (HBV) by targeting the HBV core protein, to potentially achieve a functional cure.
- The research was conducted in two phases: Phase 1 involved healthy adults receiving varying single or multiple doses of the drug to assess safety and tolerability, while Phase 2 focused on adults with chronic HBV receiving daily doses for 28 days.
- Results showed that the drug was assessed for its safety, pharmacokinetics, and antiviral effects, with findings being made available under the ClinicalTrials.gov identifier NCT02908191.
Background & Aims: NVR 3-778 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator that can inhibit HBV replication. We performed a proof-of-concept study to examine the safety, pharmacokinetics, and antiviral activity of NVR 3-778 in patients with chronic HBV infection.
Methods: We performed a phase 1 study in 73 hepatitis B envelope antigen (HBeAg)-positive patients with chronic HBV infection without cirrhosis.